Date: 2012-10-08
Type of information: Fundraising
Company: Affimed Therapeutics (Germany)
Investors: Aeris Capital (Switzerland) - BioMedInvest (Switzerland) - LSP Life Sciences Partners (The Netherlands) - Novo Nordisk (Denmark) - Orbimed (USA)
Amount: € 15.5 million
Funding type: series D financing round
Planned used: The proceeds from this transaction will be used to fund the clinical development of Affimed\'s therapeutic pipeline that consists of two TandAb products, AFM11 and AFM13.
Others: Affimed Therapeutics AG, the therapeutic TandAb antibody company, has successfully closed a Series D financing round of € 15.5 million. The proceeds from this transaction will be used to fund the clinical development of two TandAb products, AFM11 and AFM13. AFM13, a CD30/CD16A TandAb is currently being evaluated in a phase I clinical trial for the treatment of Hodgkin\'s Lymphoma. The results of the trial are expected by December 2012. AFM11 a CD19/CD3 TandAb is in the late stage preclinical development and it is expected to enter phase I clinical studies in 2013. Both candidates have unique properties as shown in preclinical studies.
TandAbs® are tetravalent bispecific antibody formats that have two binding sites for each antigen. RECRUIT-TandAbs®, such as AFM11 and AFM13, bind to target molecules on the surface of tumor cells (CD19 and CD30, respectively) and can activate immune effector cells such as cytotoxic T-cells or natural killer (NK) cells.
Therapeutic area: Cancer - Oncology
